{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:28:11Z","timestamp":1776133691034,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00762-6","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:43:33Z","timestamp":1748857413000},"page":"1695-1704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-8196","authenticated-orcid":false,"given":"Stefan","family":"Braune","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Dirks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seya","family":"Colloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanic","family":"Heer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mel","family":"Z\u00fcrcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnfin","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the NeuroTransData Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"Suppl 2","key":"762_CR1","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1007\/s10198-006-0384-8","volume":"7","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ. 2006;7(Suppl 2):S34-44.","journal-title":"Eur J Health Econ"},{"issue":"2_suppl","key":"762_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1352458517708141","volume":"23","author":"P Flachenecker","year":"2017","unstructured":"Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany. Mult Scler. 2017;23(2_suppl):78\u201390.","journal-title":"Mult Scler"},{"issue":"1","key":"762_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/pharmaceutics16010120","volume":"16","author":"CY Lee","year":"2024","unstructured":"Lee CY, Chan KH. Personalized use of disease-modifying therapies in multiple sclerosis. Pharmaceutics. 2024;16(1):120.","journal-title":"Pharmaceutics"},{"issue":"1","key":"762_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","volume":"28","author":"H Tan","year":"2011","unstructured":"Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51\u201361.","journal-title":"Adv Ther"},{"key":"762_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40801-021-00251-w","volume":"8","author":"L Freeman","year":"2021","unstructured":"Freeman L, Kee A, Tian M, Mehta R. Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy. Drugs Real World Outcomes. 2021;8:497\u2013508.","journal-title":"Drugs Real World Outcomes"},{"key":"762_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-021-00319-3","volume":"11","author":"G Pardo","year":"2022","unstructured":"Pardo G, Pineda ED, Ng CD, Bawa KK, Sheinson D, Bonine NG. Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24\u00a0months: a retrospective claims analysis. Neurol Ther. 2022;11:337\u201351.","journal-title":"Neurol Ther"},{"key":"762_CR7","first-page":"639","volume":"27","author":"NJ Engmann","year":"2021","unstructured":"Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data. J Manag Care Spec Pharm. 2021;27:639\u201349.","journal-title":"J Manag Care Spec Pharm"},{"key":"762_CR8","first-page":"1","volume":"3","author":"J Nicholas","year":"2017","unstructured":"Nicholas J, Ko JJ, Park Y, et al. Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients. Mult Scler J Exp Transl Clin. 2017;3:1\u20139.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"5","key":"762_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3111\/13696998.2015.1134546","volume":"19","author":"NP Thomas","year":"2016","unstructured":"Thomas NP, Curkendall S, Farr AM, Yu E, Hurley D. The impact of persistence with therapy on inpatient admissions and emergency room visits in the U.S. among patients with multiple sclerosis. J Med Econ. 2016;19(5):497\u2013505.","journal-title":"J Med Econ"},{"issue":"1","key":"762_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3111\/13696990903579501","volume":"13","author":"MW Reynolds","year":"2010","unstructured":"Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13(1):90\u20138.","journal-title":"J Med Econ"},{"key":"762_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2021.633427","volume":"3","author":"A Bergmann","year":"2021","unstructured":"Bergmann A, Stangel M, Weih M, et al. Development of registry data to create interactive doctor-patient platforms for personalized patient care, taking the example of the DESTINY System. Front Digit Health. 2021;3:633427.","journal-title":"Front Digit Health"},{"issue":"1","key":"762_CR12","doi-asserted-by":"publisher","first-page":"ooac017","DOI":"10.1093\/jamiaopen\/ooac017","volume":"5","author":"K Wehrle","year":"2022","unstructured":"Wehrle K, Tozzi V, Braune S, et al. Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data (RWD) in the NeuroTransData (NTD) registry. JAMIA Open. 2022;5(1):ooac017.","journal-title":"JAMIA Open"},{"key":"762_CR13","doi-asserted-by":"publisher","first-page":"175628642110396","DOI":"10.1177\/17562864211039648","volume":"14","author":"H Wiendl","year":"2021","unstructured":"Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648.","journal-title":"Ther Adv Neurol Disord"},{"key":"762_CR14","unstructured":"Hemmer B, et al. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie, 2024, In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien). Accessed 7 Apr 2025."},{"issue":"4","key":"762_CR15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s40120-022-00404-1","volume":"11","author":"L Araujo","year":"2022","unstructured":"Araujo L, Geertsen SS, Amedume A, Higuchi K, van Wingerden J. Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study. Neurol Ther. 2022;11(4):1735\u201348.","journal-title":"Neurol Ther"},{"key":"762_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102124","volume":"42","author":"F Patti","year":"2020","unstructured":"Patti F, Chisari CG, D\u2019Amico E, et al. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Mult Scler Relat Disord. 2020;42:102124.","journal-title":"Mult Scler Relat Disord"},{"issue":"1 Suppl A","key":"762_CR17","first-page":"24","volume":"19","author":"J Menzin","year":"2013","unstructured":"Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):24-S40.","journal-title":"J Manag Care Pharm"},{"issue":"7","key":"762_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16289","volume":"31","author":"EC Tallantyre","year":"2024","unstructured":"Tallantyre EC, Dobson R, Froud JLJ, et al. Real-world persistence of multiple sclerosis disease-modifying therapies. Eur J Neurol. 2024;31(7):e16289.","journal-title":"Eur J Neurol"},{"issue":"1","key":"762_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","volume":"13","author":"M Amin","year":"2023","unstructured":"Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2023;13(1):47\u201370.","journal-title":"Neurodegener Dis Manag"},{"key":"762_CR20","unstructured":"Hauser SL, Giovannoni G, Filippi M, et al. The patient impact of 11\u00a0years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase\u00a0III OPERA and ORATORIO studies. Poster presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 18\u201320 September 2024; Copenhagen, Denmark.2024 (P1664)."},{"key":"762_CR21","unstructured":"Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: up to 11\u00a0years of updated analysis in patients with relapsing and progressive multiple sclerosis. Poster presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 18\u201320 September 2024; Copenhagen, Denmark.2024 (P300)."},{"key":"762_CR22","unstructured":"EMA RWD Catalogues. An observational study of ocrelizumab treated patients with multiple sclerosis to determine the incidence and mortality rates of breast cancer and all malignancies (VERISMO Study). EU PAS number: EUPAS30752. https:\/\/catalogues.ema.europa.eu\/node\/2960\/administrative-details. Accessed Dec 10 2024."},{"key":"762_CR23","unstructured":"EMA RWD Catalogues. Long-term surveillance of ocrelizumab treated patients with multiple sclerosis (MANUSCRIPT Study). EU PAS number: EUPAS28619. https:\/\/catalogues.ema.europa.eu\/node\/2050\/administrative-details. Accessed Dec 10 2024."},{"key":"762_CR24","unstructured":"EMA RWD Catalogues. Safety and effectiveness of ocrelizumab under real world conditions: a non-interventional post authorization safety study in patients diagnosed with relapsing or primary progressive multiple sclerosis (CONFIDENCE). EU PAS number: EUPAS22951. https:\/\/catalogues.ema.europa.eu\/node\/3142\/administrative-details. Accessed Dec 10 2024."},{"key":"762_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s13104-016-2243-8","volume":"9","author":"P Wicks","year":"2016","unstructured":"Wicks P, Rasouliyan L, Katic B, et al. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. BMC Res Notes. 2016;9:434.","journal-title":"BMC Res Notes"},{"issue":"9","key":"762_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1177\/1352458518790390","volume":"25","author":"F Sacc\u00e0","year":"2019","unstructured":"Sacc\u00e0 F, Lanzillo R, Signori A, et al. Determinants of therapy switch in multiple sclerosis treatment-na\u00efve patients: a real-life study. Mult Scler. 2019;25(9):1263\u201372.","journal-title":"Mult Scler"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00762-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00762-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:39:36Z","timestamp":1757176776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00762-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00762-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stefan Braune received honoraria from Kassen\u00e4rztliche Vereinigung Bayerns and health maintenance organizations for patient care; and from, Merck, NeuroTransData, Novartis, Sanofi and Roche for consulting, project management, clinical studies, and lectures; he also received honoraria and expense compensation as a board member of NeuroTransData. Petra Dirks was an employee of F. Hoffmann-La Roche Ltd during completion of this work and is a shareholder in F. Hoffmann-La Roche Ltd; her current affiliation is Carl-von-Ossietzky University, Oldenburg, Germany. Seya Colloud is an employee of and a shareholder in F. Hoffmann-La Roche Ltd. Evan Davies is an employee of and a shareholder in F. Hoffmann-La Roche Ltd. Qing Wang is an employee of and a shareholder in F. Hoffmann-La Roche Ltd. Yanic Heer was contracted to perform statistical projects for NeuroTransData and was an employee of PricewaterhouseCoopers AG during completion of this work. Mel Z\u00fcrcher was contracted to perform statistical projects for NeuroTransData and was an employee of PricewaterhouseCoopers AG during completion of this work. Diana Sun is an employee of Genentech, Inc., and a shareholder in F. Hoffmann-La Roche Ltd. Arnfin Bergmann received consultancy fees from advisory board, speaker, and other activities for NeuroTransData; project management and clinical studies from Novartis and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data acquisition protocol was approved by the ethical committee of the Bavarian Medical Board (Bayerische Landes\u00e4rztekammer, June 14, 2012, No. 11144) and reapproved by the ethical committee of the Medical Board North-Rhine (\u00c4rztekammer Nordrhein, April 25, 2017, ID 2017071). The study conforms to the World Medical Association Declaration of Helsinki as published on the website of the Journal of American Medical Association, the Guidelines for Good Pharmacoepidemiology\u00a0Practices (GPP) published by the International Society of Pharmacoepidemiology (ISPE), and the laws and regulations of Germany. Patient inclusion with informed consent is completed in the respective NTD practice as part of routine clinical care. Patients included in this analysis provided their informed consent (via tablets in NTD practices, electronic questionnaires, or via a patient portal) to the NTD registry. Patients explicitly agreed to secondary use of their data. All personnel undergo regular training to ensure quality of data in the registry. Both automatic and manually executed queries are implemented to further ensure data quality []. All data are pseudonymized and pooled to form the NTD registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}